Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study that follows adults starting GLP-1 receptor agonist therapy for obesity and compares their 24-month weight loss to historical data from adults who underwent laparoscopic sleeve gastrectomy at the same center. Treatment choices are made in routine care, not by the study, and the two groups are matched on baseline characteristics to balance differences. The primary outcome is the percentage of starting body weight lost at 24 months, with secondary assessments including earlier weight changes, adverse effects, continuation or stopping reasons, and changes in weight-related conditions. No randomization or experimental assignment is involved, and data are drawn from real-world practice at a single center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

GLP-1 Receptor Agonist Cohort:

* Age 18 years or older at treatment initiation.
* Initiation of a GLP-1 receptor agonist for obesity or overweight as part of routine clinical care.
* Available baseline height and body weight measurements.
* Willingness to attend at least one follow-up assessment.
* Ability to comply with the center's standard follow-up program.
* Provision of written informed consent.

Laparoscopic Sleeve Gastrectomy Cohort:

* Age 18 years or older at surgery.
* Primary laparoscopic sleeve gastrectomy for obesity performed at the study center between January 1, 2020, and January 1, 2026.
* Available preoperative height, body weight, and body mass index measurements.
* Available demographic and baseline clinical data.
* At least one documented postoperative body weight measurement. Availability of a 24-month weight measurement is preferred for the primary comparison.

Exclusion Criteria:

Both Cohorts:

* Bariatric or metabolic surgery before the index treatment.
* Revisional bariatric surgery as the index treatment.
* Active malignancy or a serious systemic disease substantially affecting body weight.
* Pregnancy or breastfeeding at the index treatment.
* Uncontrolled endocrine disease that may cause weight loss.
* Missing baseline height or body weight measurements.
* Recent participation in another intensive weight-loss program before the index treatment.
* Concurrent use of another anti-obesity treatment that could substantially affect study outcomes.
* Inability to reliably verify study data.

GLP-1 Receptor Agonist Cohort:

* Short-term GLP-1 receptor agonist use for an indication other than weight management.
* Medication prescribed but never administered.

Laparoscopic Sleeve Gastrectomy Cohort:

* Sleeve gastrectomy performed concurrently with another bariatric procedure.
* Sleeve gastrectomy performed for an indication other than primary obesity treatment.

Where it's running

• Yüzüncü Yıl University
  Van, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Sebahattin Çelik
• Email: s.celik@yyu.edu.tr
• Phone: +90 505 705 79 57

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How incretin treatments affect muscle mass and function in people with overweight or obesity

  This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.

  Recruiting Radboud University Medical Center · Amsterdam and 1 other locations · NCT07929831

• Dose find for remimazolam plus alfentanil for gastroscopy in obese adults

  This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07925684

• Gut barrier and inflammation after fast-food overfeeding in adults

  This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.

  Recruiting University Hospital, Gentofte, Copenhagen · Hellerup · NCT07893743

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• GLP-1 weight‑loss medicine: finding who will benefit most

  This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.

  Recruiting Phase 4 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07870538

• Long-term Iron Absorption in Women with Overweight/Obesity vs Normal Weight

  This study tests long-term iron absorption and loss in women aged 40–50, comparing those who are overweight/obese with those of normal weight.

  Recruiting Mahidol University · Nakhon Pathom · NCT07855939

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.